Investment, Funding & Disinvestments

The three day conference will take place at the EJS Ministerial Complex in Congo Town and will bring together scientists, researchers, healthcare workers, students, surveillance officers, academics and international experts.

The share repurchase programme will be funded primarily through proceeds from the sale of an approximately 6% stake in Gland Pharma for about US$294 million.

The GPP Guidelines set out standards for key pharmacy services, including the sourcing and storage of medicines, prescription assessment, accurate dispensing, patient counselling, confidentiality and record keeping.

The new APU features natural lighting, well ventilated wards and two secure courtyards designed to create calmer surroundings for patients.

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.

The approach is intended to support drug discovery in neurology, where diseases often arise from complex interactions involving genetic, developmental, neural network, immune and environmental factors.

The facility replaces the company’s former OSD Customer Center in nearby Waiblingen and brings laboratories, production equipment and manufacturing facilities closer together.

The partnership, developed through sustained engagement led by UNAIDS, is being advanced this week through a SADC-China strategic exchange taking place from 31 August to 4 September 2026 in Johannesburg, Durban and Cape Town.

The acquisition adds rare endocrine diseases as a new growth area alongside Vertex’s existing focus on cystic fibrosis, hematology, acute pain and renal disease.